Genotype Differences and Hydroxyurea Utilization Among Adults With Moderate to Severe Sickle Cell Disease
Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · 2026
DOI: 10.1002/phar.70099 ↗At a glance
Journal article in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2026. Written by Siang-Hao Cheng and 4 co-authors. Institution: Department of Pharmacy & Therapeutics, University of Pittsburgh School of Pharmacy, Pittsburgh, Pennsylvania, USA. Major MEDLINE topics: Hydroxyurea, Anemia, Sickle Cell, Antisickling Agents. Cited 1 times so far (Crossref); 48 references. The full text is freely available (open access, CC BY 4.0).
Abstract (original language)
Backgrounds Hydroxyurea (HU) remains underutilized in adults with sickle cell disease (SCD) despite proven benefits. Current HU guidelines primarily target sickle cell anemia (SCA), overlooking other genotypes.
Objectives
This study examined HU utilization patterns across genotypes among adults considered to have moderate to severe SCD manifestations by the 2014 National Heart, Lung, and Blood Institute (NHLBI) guideline criteria and identified factors associated with early HU use.
Methods
This retrospective cohort study analyzed electronic health records from the University of Pittsburgh Medical Center (2014–2024) of adults with SCD experiencing three or more vaso‐occlusive crises (VOCs) within 12 months. HU utilization rates, stratified by genotype, were assessed at 30‐, 90‐, 180‐, and 365‐day intervals after the third VOC episode ( index date ). Multivariable logistic regression was used to identify factors associated with HU use within 90 days post‐index.
Results
Among 411 adults with moderate to severe SCD (≥ 3 VOCs within a year), with a mean age of 42.4 ± 17.9 years and 61.3% female, only 19.5% received HU within 90 days post‐index. Although 42.8% of SCA patients received HU within 1 year, only 8.0% of non‐SCA patients received the treatment. The SCA genotype was the strongest predictor of HU use (odds ratio [OR] = 4.5, 95% confidence interval [CI]: 2.4–8.7), followed by pulmonary complications. Additional barriers included older age.
Conclusion
Despite guideline recommendations since 2014, HU remains underutilized. Non‐SCA patients meeting the severity threshold for HU use are consistently undertreated, highlighting an urgent need for studies establishing HU safety and efficacy in non‐SCA genotypes. Future studies should also address age barriers to optimize HU use.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Pharmacy & Therapeutics, University of Pittsburgh School of Pharmacy, Pittsburgh, Pennsylvania, USA.
- University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
- The University of Texas at Austin College of Pharmacy Health Outcomes Division, Austin, Texas, USA.
ORCID profiles: Siang-Hao Cheng, Enrico M Novelli, Hyeun Ah Kang, Kangho Suh
Cite
APA
Cheng, S. H., Novelli, E. M., Kang, H. A., Newman, T. V., & Suh, K. (2026). Genotype Differences and Hydroxyurea Utilization Among Adults With Moderate to Severe Sickle Cell Disease. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. https://doi.org/10.1002/phar.70099
Vancouver
Cheng SH, Novelli EM, Kang HA, Newman TV, Suh K. Genotype Differences and Hydroxyurea Utilization Among Adults With Moderate to Severe Sickle Cell Disease. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. 2026. doi:10.1002/phar.70099
BibTeX
@article{Cheng2026,
author = {Cheng, Siang-Hao and Novelli, Enrico M and Kang, Hyeun Ah and Newman, Terri V and Suh, Kangho},
title = {Genotype Differences and Hydroxyurea Utilization Among Adults With Moderate to Severe Sickle Cell Disease},
journal = {Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy},
year = {2026},
doi = {10.1002/phar.70099}
}
EUVIMED